Can a vaccine mix help the body fight HIV? early trial begins

NCT ID NCT07182838

Ongoing Disease control Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a combination of HIV GP160 protein and BCG vaccine (used for tuberculosis) in 20 HIV-positive people without AIDS symptoms. The goal is to see if the mix can activate the immune system to recognize and kill HIV. It is a small proof-of-concept study, not a large effectiveness trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIV GP160 plus BCG vaccine mix
What this could lead to: If it works, this could point toward a new way to help the immune system control HIV without lifelong medication.
What could go wrong: This is a very early, small proof-of-concept trial with only 20 participants. It is designed to test safety and basic activity, not to prove effectiveness. Many early-stage ideas do not lead to approved treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Medicine Invention Design Incorporation - IORG0007849 - NPI 1023387701

Rockville, Maryland, 20853, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.